Advanced search
1 file | 907.02 KB Add to list

A comprehensive overview of genomic imprinting in breast and its deregulation in cancer

Tine Goovaerts (UGent) , Sandra Steyaert (UGent) , Chari Vandenbussche, Jeroen Galle (UGent) , Olivier Thas (UGent) , Wim Van Criekinge (UGent) and Tim De Meyer (UGent)
Author
Organization
Abstract
Genomic imprinting plays an important role in growth and development. Loss of imprinting (LOI) has been found in cancer, yet systematic studies are impeded by data-analytical challenges. We developed a methodology to detect monoallelically expressed loci without requiring genotyping data, and applied it on The Cancer Genome Atlas (TCGA, discovery) and Genotype-Tissue expression project (GTEx, validation) breast tissue RNA-seq data. Here, we report the identification of 30 putatively imprinted genes in breast. In breast cancer (TCGA), HM13 is featured by LOI and expression upregulation, which is linked to DNA demethylation. Other imprinted genes typically demonstrate lower expression in cancer, often associated with copy number variation and aberrant DNA methylation. Downregulation in cancer frequently leads to higher relative expression of the (imperfectly) silenced allele, yet this is not considered canonical LOI given the lack of (absolute) re-expression. In summary, our novel methodology highlights the massive deregulation of imprinting in breast cancer.
Keywords
DNA METHYLATION, GENE NETWORK, FREQUENT LOSS, IGF2, EXPRESSION, GROWTH, RISK, SIGNATURES, LANDSCAPE, CHROMATIN

Downloads

  • NatComImprinting2018.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 907.02 KB

Citation

Please use this url to cite or link to this publication:

MLA
Goovaerts, Tine, et al. “A Comprehensive Overview of Genomic Imprinting in Breast and Its Deregulation in Cancer.” NATURE COMMUNICATIONS, vol. 9, 2018, doi:10.1038/s41467-018-06566-7.
APA
Goovaerts, T., Steyaert, S., Vandenbussche, C., Galle, J., Thas, O., Van Criekinge, W., & De Meyer, T. (2018). A comprehensive overview of genomic imprinting in breast and its deregulation in cancer. NATURE COMMUNICATIONS, 9. https://doi.org/10.1038/s41467-018-06566-7
Chicago author-date
Goovaerts, Tine, Sandra Steyaert, Chari Vandenbussche, Jeroen Galle, Olivier Thas, Wim Van Criekinge, and Tim De Meyer. 2018. “A Comprehensive Overview of Genomic Imprinting in Breast and Its Deregulation in Cancer.” NATURE COMMUNICATIONS 9. https://doi.org/10.1038/s41467-018-06566-7.
Chicago author-date (all authors)
Goovaerts, Tine, Sandra Steyaert, Chari Vandenbussche, Jeroen Galle, Olivier Thas, Wim Van Criekinge, and Tim De Meyer. 2018. “A Comprehensive Overview of Genomic Imprinting in Breast and Its Deregulation in Cancer.” NATURE COMMUNICATIONS 9. doi:10.1038/s41467-018-06566-7.
Vancouver
1.
Goovaerts T, Steyaert S, Vandenbussche C, Galle J, Thas O, Van Criekinge W, et al. A comprehensive overview of genomic imprinting in breast and its deregulation in cancer. NATURE COMMUNICATIONS. 2018;9.
IEEE
[1]
T. Goovaerts et al., “A comprehensive overview of genomic imprinting in breast and its deregulation in cancer,” NATURE COMMUNICATIONS, vol. 9, 2018.
@article{8576972,
  abstract     = {{Genomic imprinting plays an important role in growth and development. Loss of imprinting (LOI) has been found in cancer, yet systematic studies are impeded by data-analytical challenges. We developed a methodology to detect monoallelically expressed loci without requiring genotyping data, and applied it on The Cancer Genome Atlas (TCGA, discovery) and Genotype-Tissue expression project (GTEx, validation) breast tissue RNA-seq data. Here, we report the identification of 30 putatively imprinted genes in breast. In breast cancer (TCGA), HM13 is featured by LOI and expression upregulation, which is linked to DNA demethylation. Other imprinted genes typically demonstrate lower expression in cancer, often associated with copy number variation and aberrant DNA methylation. Downregulation in cancer frequently leads to higher relative expression of the (imperfectly) silenced allele, yet this is not considered canonical LOI given the lack of (absolute) re-expression. In summary, our novel methodology highlights the massive deregulation of imprinting in breast cancer.}},
  articleno    = {{4120}},
  author       = {{Goovaerts, Tine and Steyaert, Sandra and Vandenbussche, Chari and Galle, Jeroen and Thas, Olivier and Van Criekinge, Wim and De Meyer, Tim}},
  issn         = {{2041-1723}},
  journal      = {{NATURE COMMUNICATIONS}},
  keywords     = {{DNA METHYLATION,GENE NETWORK,FREQUENT LOSS,IGF2,EXPRESSION,GROWTH,RISK,SIGNATURES,LANDSCAPE,CHROMATIN}},
  language     = {{eng}},
  pages        = {{14}},
  title        = {{A comprehensive overview of genomic imprinting in breast and its deregulation in cancer}},
  url          = {{http://doi.org/10.1038/s41467-018-06566-7}},
  volume       = {{9}},
  year         = {{2018}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: